Diabetes

At Auragens, we believe in the extraordinary potential of regenerative medicine—but also in the responsibility to communicate science with integrity. Diabetes, particularly Type 1 and Type 2, remains one of the most urgent and widespread chronic diseases in the world. While headlines occasionally emerge claiming that “China has cured diabetes with stem cells,” it is essential to distinguish between social media hype and scientific reality.

In recent years, several international clinics—most notably in China—have promoted their stem cell-based treatments as a “cure” for diabetes. These claims are typically based on short-term improvements in blood sugar control and insulin independence among a limited set of patients. While these outcomes are indeed exciting, they do not constitute a cure in the true medical sense. Diabetes, especially Type 1, is a complex autoimmune and metabolic disease that requires comprehensive, long-term management.

It’s important for patients to understand: there is no verified, universally accepted cure for diabetes at this time, whether in China or anywhere else. However, there is hope—and stem cells may be part of that evolving picture.

At Auragens, we utilize umbilical cord-derived mesenchymal stem cells (UC-MSCs)—among the most studied and biologically potent regenerative cells available. These cells are known for their immunomodulatory, anti-inflammatory, and tissue-supporting properties. When administered to patients with diabetes, UC-MSCs may contribute to:

• Reduced systemic inflammation, which plays a key role in both Type 1 and Type 2 diabetes progression.

• Improved insulin sensitivity, particularly in Type 2 diabetes.

• Modulation of immune response, potentially slowing the autoimmune attack on pancreatic beta cells in Type 1 diabetes.

• Tissue microenvironment repair, promoting better vascular and metabolic function.

In some patients, particularly those in earlier stages of disease or with residual pancreatic function, insulin requirements may decrease significantly—and in select cases, patients report no longer needing insulin injections for extended periods. This is not a cure, but rather a functional remission—and even that varies by individual biology, disease stage, and overall health.

We believe in progress rooted in data. Peer-reviewed studies and clinical trials around the world—including some in the U.S., Japan, and Europe—are investigating the role of stem cells in treating diabetes. While outcomes are promising, the field is still in evolution, and the long-term durability and reproducibility of these effects require more research.

Unlike some international centers, Auragens does not promise miracles. We deliver science-backed treatment options that are personalized, physician-guided, and supported by a global medical and research advisory team. Our goal is not to mislead with the word “cure”—but to inspire hope with real, measurable improvements in quality of life, metabolic health, and independence from daily insulin in eligible patients.